LisdexAmphetamine versus Methylphenidate for pediatric patients with ADHD and type 1 diabetes
This is a multicenter, randomized, open-label, cross-over clinical trial in children and adolescents with ADHD and type 1 diabetes.
The trial will be conducted in four reference pediatric diabetes centers in Poland. Children will be randomized to methylphenidate (long-release capsule, doses 18-36-54 mg) versus lisdexamphetamine (LDX, 30-50-70 mg). Pharmacotherapy will continue for 6 months before switching to alternative medication. The primary endpoint (ADHD symptom severity, Conners 3.0 questionnaire) will be assessed by a blinded investigator.
Last updated 11/19/2024